A cell-based high-throughput screening method to directly examine transthyretin amyloid fibril formation at neutral pH
Mitsuharu Ueda,Masamitsu Okada,Mineyuki Mizuguchi,Barbara Kluve-Beckerman,Kyosuke Kanenawa,Aito Isoguchi,Yohei Misumi,Masayoshi Tasaki,Akihiko Ueda,Akinori Kanai,Ryoko Sasaki,Teruaki Masuda,Yasuteru Inoue,Toshiya Nomura,Satoru Shinriki,Tsuyoshi Shuto,Hirofumi Kai,Taro Yamashita,Hirotaka Matsui,Merrill D Benson,Yukio Ando
DOI: https://doi.org/10.1074/jbc.RA119.007851
2019-07-19
Abstract:Transthyretin (TTR) is a major amyloidogenic protein associated with hereditary (ATTRm) and nonhereditary (ATTRwt) intractable systemic transthyretin amyloidosis. The pathological mechanisms of ATTR-associated amyloid fibril formation are incompletely understood, and there is a need for identifying compounds that target ATTR. C-terminal TTR fragments are often present in amyloid-laden tissues of most patients with ATTR amyloidosis, and on the basis of in vitro studies, these fragments have been proposed to play important roles in amyloid formation. Here, we found that experimentally-formed aggregates of full-length TTR are cleaved into C-terminal fragments, which were also identified in patients' amyloid-laden tissues and in SH-SY5Y neuronal and U87MG glial cells. We observed that a 5-kDa C-terminal fragment of TTR, TTR81-127, is highly amyloidogenic in vitro, even at neutral pH. This fragment formed amyloid deposits and induced apoptosis and inflammatory gene expression also in cultured cells. Using the highly amyloidogenic TTR81-127 fragment, we developed a cell-based high-throughput screening method to discover compounds that disrupt TTR amyloid fibrils. Screening a library of 1280 off-patent drugs, we identified two candidate repositioning drugs, pyrvinium pamoate and apomorphine hydrochloride. Both drugs disrupted patient-derived TTR amyloid fibrils ex vivo, and pyrvinium pamoate also stabilized the tetrameric structure of TTR ex vivo in patient plasma. We conclude that our TTR81-127-based screening method is very useful for discovering therapeutic drugs that directly disrupt amyloid fibrils. We propose that repositioning pyrvinium pamoate and apomorphine hydrochloride as TTR amyloid-disrupting agents may enable evaluation of their clinical utility for managing ATTR amyloidosis.